Open source drug discovery- A new paradigm of collaborative research in tuberculosis drug development

Anshu Bhardwaj, Vinod Scaria, Gajendra Pal Singh Raghava, Andrew Michael Lynn, Nagasuma Chandra, Sulagna Banerjee, Muthukurussi V. Raghunandanan, Vikas Pandey, Bhupesh Taneja, Jyoti Yadav, Debasis Dash, Jaijit Bhattacharya, Amit Misra, Anil Kumar, Srinivasan Ramachandran, Zakir Thomas, Samir K. Brahmachari

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

It is being realized that the traditional closed-door and market driven approaches for drug discovery may not be the best suited model for the diseases of the developing world such as tuberculosis and malaria, because most patients suffering from these diseases have poor paying capacity. To ensure that new drugs are created for patients suffering from these diseases, it is necessary to formulate an alternate paradigm of drug discovery process. The current model constrained by limitations for collaboration and for sharing of resources with confidentiality hampers the opportunities for bringing expertise from diverse fields. These limitations hinder the possibilities of lowering the cost of drug discovery. The Open Source Drug Discovery project initiated by Council of Scientific and Industrial Research, India has adopted an open source model to power wide participation across geographical borders. Open Source Drug Discovery emphasizes integrative science through collaboration, open-sharing, taking up multi-faceted approaches and accruing benefits from advances on different fronts of new drug discovery. Because the open source model is based on community participation, it has the potential to self-sustain continuous development by generating a storehouse of alternatives towards continued pursuit for new drug discovery. Since the inventions are community generated, the new chemical entities developed by Open Source Drug Discovery will be taken up for clinical trial in a non-exclusive manner by participation of multiple companies with majority funding from Open Source Drug Discovery. This will ensure availability of drugs through a lower cost community driven drug discovery process for diseases afflicting people with poor paying capacity. Hopefully what LINUX the World Wide Web have done for the information technology, Open Source Drug Discovery will do for drug discovery.

Original languageEnglish (US)
Pages (from-to)479-486
Number of pages8
JournalTuberculosis
Volume91
Issue number5
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Drug Discovery
Tuberculosis
Research
Pharmaceutical Preparations
Costs and Cost Analysis
Confidentiality
Internet
Malaria
India
Clinical Trials
Technology

Keywords

  • Drug Discovery
  • Generics
  • Malaria
  • Neglected diseases
  • Open source
  • Tuberculosis

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Bhardwaj, A., Scaria, V., Raghava, G. P. S., Lynn, A. M., Chandra, N., Banerjee, S., ... Brahmachari, S. K. (2011). Open source drug discovery- A new paradigm of collaborative research in tuberculosis drug development. Tuberculosis, 91(5), 479-486. https://doi.org/10.1016/j.tube.2011.06.004

Open source drug discovery- A new paradigm of collaborative research in tuberculosis drug development. / Bhardwaj, Anshu; Scaria, Vinod; Raghava, Gajendra Pal Singh; Lynn, Andrew Michael; Chandra, Nagasuma; Banerjee, Sulagna; Raghunandanan, Muthukurussi V.; Pandey, Vikas; Taneja, Bhupesh; Yadav, Jyoti; Dash, Debasis; Bhattacharya, Jaijit; Misra, Amit; Kumar, Anil; Ramachandran, Srinivasan; Thomas, Zakir; Brahmachari, Samir K.

In: Tuberculosis, Vol. 91, No. 5, 01.09.2011, p. 479-486.

Research output: Contribution to journalReview article

Bhardwaj, A, Scaria, V, Raghava, GPS, Lynn, AM, Chandra, N, Banerjee, S, Raghunandanan, MV, Pandey, V, Taneja, B, Yadav, J, Dash, D, Bhattacharya, J, Misra, A, Kumar, A, Ramachandran, S, Thomas, Z & Brahmachari, SK 2011, 'Open source drug discovery- A new paradigm of collaborative research in tuberculosis drug development', Tuberculosis, vol. 91, no. 5, pp. 479-486. https://doi.org/10.1016/j.tube.2011.06.004
Bhardwaj, Anshu ; Scaria, Vinod ; Raghava, Gajendra Pal Singh ; Lynn, Andrew Michael ; Chandra, Nagasuma ; Banerjee, Sulagna ; Raghunandanan, Muthukurussi V. ; Pandey, Vikas ; Taneja, Bhupesh ; Yadav, Jyoti ; Dash, Debasis ; Bhattacharya, Jaijit ; Misra, Amit ; Kumar, Anil ; Ramachandran, Srinivasan ; Thomas, Zakir ; Brahmachari, Samir K. / Open source drug discovery- A new paradigm of collaborative research in tuberculosis drug development. In: Tuberculosis. 2011 ; Vol. 91, No. 5. pp. 479-486.
@article{c46ab3c441c34ff18f35ea377b4a5fc6,
title = "Open source drug discovery- A new paradigm of collaborative research in tuberculosis drug development",
abstract = "It is being realized that the traditional closed-door and market driven approaches for drug discovery may not be the best suited model for the diseases of the developing world such as tuberculosis and malaria, because most patients suffering from these diseases have poor paying capacity. To ensure that new drugs are created for patients suffering from these diseases, it is necessary to formulate an alternate paradigm of drug discovery process. The current model constrained by limitations for collaboration and for sharing of resources with confidentiality hampers the opportunities for bringing expertise from diverse fields. These limitations hinder the possibilities of lowering the cost of drug discovery. The Open Source Drug Discovery project initiated by Council of Scientific and Industrial Research, India has adopted an open source model to power wide participation across geographical borders. Open Source Drug Discovery emphasizes integrative science through collaboration, open-sharing, taking up multi-faceted approaches and accruing benefits from advances on different fronts of new drug discovery. Because the open source model is based on community participation, it has the potential to self-sustain continuous development by generating a storehouse of alternatives towards continued pursuit for new drug discovery. Since the inventions are community generated, the new chemical entities developed by Open Source Drug Discovery will be taken up for clinical trial in a non-exclusive manner by participation of multiple companies with majority funding from Open Source Drug Discovery. This will ensure availability of drugs through a lower cost community driven drug discovery process for diseases afflicting people with poor paying capacity. Hopefully what LINUX the World Wide Web have done for the information technology, Open Source Drug Discovery will do for drug discovery.",
keywords = "Drug Discovery, Generics, Malaria, Neglected diseases, Open source, Tuberculosis",
author = "Anshu Bhardwaj and Vinod Scaria and Raghava, {Gajendra Pal Singh} and Lynn, {Andrew Michael} and Nagasuma Chandra and Sulagna Banerjee and Raghunandanan, {Muthukurussi V.} and Vikas Pandey and Bhupesh Taneja and Jyoti Yadav and Debasis Dash and Jaijit Bhattacharya and Amit Misra and Anil Kumar and Srinivasan Ramachandran and Zakir Thomas and Brahmachari, {Samir K.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.tube.2011.06.004",
language = "English (US)",
volume = "91",
pages = "479--486",
journal = "Tuberculosis",
issn = "1472-9792",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Open source drug discovery- A new paradigm of collaborative research in tuberculosis drug development

AU - Bhardwaj, Anshu

AU - Scaria, Vinod

AU - Raghava, Gajendra Pal Singh

AU - Lynn, Andrew Michael

AU - Chandra, Nagasuma

AU - Banerjee, Sulagna

AU - Raghunandanan, Muthukurussi V.

AU - Pandey, Vikas

AU - Taneja, Bhupesh

AU - Yadav, Jyoti

AU - Dash, Debasis

AU - Bhattacharya, Jaijit

AU - Misra, Amit

AU - Kumar, Anil

AU - Ramachandran, Srinivasan

AU - Thomas, Zakir

AU - Brahmachari, Samir K.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - It is being realized that the traditional closed-door and market driven approaches for drug discovery may not be the best suited model for the diseases of the developing world such as tuberculosis and malaria, because most patients suffering from these diseases have poor paying capacity. To ensure that new drugs are created for patients suffering from these diseases, it is necessary to formulate an alternate paradigm of drug discovery process. The current model constrained by limitations for collaboration and for sharing of resources with confidentiality hampers the opportunities for bringing expertise from diverse fields. These limitations hinder the possibilities of lowering the cost of drug discovery. The Open Source Drug Discovery project initiated by Council of Scientific and Industrial Research, India has adopted an open source model to power wide participation across geographical borders. Open Source Drug Discovery emphasizes integrative science through collaboration, open-sharing, taking up multi-faceted approaches and accruing benefits from advances on different fronts of new drug discovery. Because the open source model is based on community participation, it has the potential to self-sustain continuous development by generating a storehouse of alternatives towards continued pursuit for new drug discovery. Since the inventions are community generated, the new chemical entities developed by Open Source Drug Discovery will be taken up for clinical trial in a non-exclusive manner by participation of multiple companies with majority funding from Open Source Drug Discovery. This will ensure availability of drugs through a lower cost community driven drug discovery process for diseases afflicting people with poor paying capacity. Hopefully what LINUX the World Wide Web have done for the information technology, Open Source Drug Discovery will do for drug discovery.

AB - It is being realized that the traditional closed-door and market driven approaches for drug discovery may not be the best suited model for the diseases of the developing world such as tuberculosis and malaria, because most patients suffering from these diseases have poor paying capacity. To ensure that new drugs are created for patients suffering from these diseases, it is necessary to formulate an alternate paradigm of drug discovery process. The current model constrained by limitations for collaboration and for sharing of resources with confidentiality hampers the opportunities for bringing expertise from diverse fields. These limitations hinder the possibilities of lowering the cost of drug discovery. The Open Source Drug Discovery project initiated by Council of Scientific and Industrial Research, India has adopted an open source model to power wide participation across geographical borders. Open Source Drug Discovery emphasizes integrative science through collaboration, open-sharing, taking up multi-faceted approaches and accruing benefits from advances on different fronts of new drug discovery. Because the open source model is based on community participation, it has the potential to self-sustain continuous development by generating a storehouse of alternatives towards continued pursuit for new drug discovery. Since the inventions are community generated, the new chemical entities developed by Open Source Drug Discovery will be taken up for clinical trial in a non-exclusive manner by participation of multiple companies with majority funding from Open Source Drug Discovery. This will ensure availability of drugs through a lower cost community driven drug discovery process for diseases afflicting people with poor paying capacity. Hopefully what LINUX the World Wide Web have done for the information technology, Open Source Drug Discovery will do for drug discovery.

KW - Drug Discovery

KW - Generics

KW - Malaria

KW - Neglected diseases

KW - Open source

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=80052698379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052698379&partnerID=8YFLogxK

U2 - 10.1016/j.tube.2011.06.004

DO - 10.1016/j.tube.2011.06.004

M3 - Review article

C2 - 21782516

AN - SCOPUS:80052698379

VL - 91

SP - 479

EP - 486

JO - Tuberculosis

JF - Tuberculosis

SN - 1472-9792

IS - 5

ER -